A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

Inclusion criteria: * Written informed consent in accordance with International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines and local legislation and/or regulations * Confirmed diagnosis of Cerebral Venous or dural sinus thrombosis (CVT), with or without intracranial haemorrhage * Completion of anticoagulation therapy for 5-15 days which has been administered until randomisation; anticoagulation must include full-dose low molecular weight heparin or unfractionated heparin * Eligibility for treatment with an oral anticoagulant * Further inclusion criteria apply Exclusion criteria: * Cerebral Venous or dural sinus thrombosis (CVT) associated with central nervous system infection or due to head trauma * Planned surgical treatment for CVT * Conditions associated with increased risk of bleeding * History of symptomatic non-traumatic intracranial haemorrhage with risk of recurrence according to Investigator judgment * Treatment with an antithrombotic regimen for an indication other than CVT and requiring continuation of that treatment for the original diagnosis without change in the regimen * Severe renal impairment * Active liver disease * Pregnancy, nursing or planning to become pregnant while in the trial * Further exclusion criteria apply